 |
88 Diseases |  |
13 Trials |
|
13 Trials |  |
791 News |  |
| «123456789101112» |
- Epogen, Procrit (epoetin alfa) / Amgen, Evrenzo (roxadustat) / Astellas, AstraZeneca, FibroGen
[VIRTUAL] Efficacy and Safety of Roxadustat in Patients with Dialysis-Dependent CKD and Anemia on Peritoneal Dialysis (Simulive) - Oct 11, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_3739;
Roxadustat was efficacious vs. epoetin alfa for increasing/maintaining Hb levels and reducing the risk for blood/RBC transfusion in patients with DD-CKD on PD. Safety and tolerability profiles were similar to the overall population and consistent with that observed in this patient subgroup.
- Epogen, Procrit (epoetin alfa) / Amgen, Evrenzo (roxadustat) / Astellas, AstraZeneca, FibroGen
[VIRTUAL] Pooled Analyses of the Phase 3 Roxadustat Studies: Congestive Heart Failure Hospitalization Rates in Dialysis and Non-Dialysis Patients with Anemia Treated with Roxadustat vs. Comparators (Simulive) - Oct 11, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_3640;
Roxadustat showed a 27% reduction in risk for CHF hospitalization compared to epoetin alfa in the DD population, and a trend based on the point estimates toward reduction of risk compared to placebo in NDD, and to epoetin alfa in ID-DD patients. Funding: Commercial Support
- Epogen, Procrit (epoetin alfa) / Amgen, Evrenzo (roxadustat) / Astellas, AstraZeneca, FibroGen
[VIRTUAL] Efficacy and Safety of Roxadustat in Patients with Dialysis-Dependent CKD and Anemia on Hemodialysis (Simulive) - Oct 11, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_3554;
Roxadustat was efficacious vs. epoetin alfa for increasing and maintaining Hb levels in patients with DD-CKD on HD. The safety and tolerability profiles were similar to the overall population and consistent with that observed in this patient subgroup.
- Epogen, Procrit (epoetin alfa) / Amgen
[VIRTUAL] Adverse Event Rates Are Higher Post-Transfusion vs. Overall Follow-up and Independent of Background Anemia Treatment in Patients with CKD (Simulive) - Oct 11, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_3408;
The reduction in transfusions for patients taking roxadustat could lower patient risk and healthcare resource use in managing CKD-related anemia. Funding: Commercial Support
- Epogen, Procrit (epoetin alfa) / Amgen, Evrenzo (roxadustat) / Astellas, AstraZeneca, FibroGen
[VIRTUAL] Hemoglobin (Hb) Correction with Roxadustat Is Associated with Improved Iron Homeostasis in Patients with Dialysis-Dependent CKD (DD-CKD) (Simulive) - Oct 11, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_3407;
Overall, these changes contributed to decreased need for IV iron use while achieving greater Hb increase from baseline with roxadustat vs epoetin alfa. Funding: Commercial Support
- Epogen, Procrit (epoetin alfa) / Amgen, Evrenzo (roxadustat) / Astellas, AstraZeneca, FibroGen
[VIRTUAL] Roxadustat Is Not Associated with an Increased Risk of Neoplasm in Patients with CKD and Anemia (Simulive) - Oct 11, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_3406;
There were no clinically meaningful between–treatment-group differences in neoplasm-related AE and SAE rates in the roxadustat phase 3 clinical trials. Funding: Commercial Support
- Desferal (deferoxamine) / Kermanshah University of Medical Sciences, Novartis, Epogen, Procrit (epoetin alfa) / Amgen
[VIRTUAL] Iron Overload in ESRD Treated with Deferoxamine for Chelation (On-Demand) - Oct 11, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_2465;
While no repeat iron levels have been obtained due to patient discharge, initial ferritin levels indicate possible treatment response. No adverse side effects have been noted with the patient receiving chelation therapy during her hospital admission.
- Epogen, Procrit (epoetin alfa) / Amgen, Evrenzo (roxadustat) / Astellas, AstraZeneca, FibroGen
[VIRTUAL] Efficacy and Safety of Roxadustat in Patients with Dialysis-Dependent CKD, Anemia, and Diabetes Mellitus (On-Demand) - Oct 11, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_1802;
Safety and tolerability profiles were similar to the overall population and consistent with that observed in this patient subgroup. Funding: Commercial Support
- Epogen, Procrit (epoetin alfa) / Amgen, Evrenzo (roxadustat) / Astellas, AstraZeneca, FibroGen
[VIRTUAL] Roxadustat vs. Placebo or Epoetin Alfa Has No Clinically Meaningful Effect on Blood Pressure in Patients with Anemia of CKD (On-Demand) - Oct 11, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_1587;
Pooled analyses of phase 3 data across a continuum of patients with CKD and anemia showed that roxadustat did not have any clinically meaningful effect on BP, HTN exacerbation, or hypertensive emergency vs. placebo in NDD-NDD patients and epoetin alfa in DD patients. Funding: Commercial Support
- Epogen, Procrit (epoetin alfa) / Amgen, Evrenzo (roxadustat) / Astellas, AstraZeneca, FibroGen
[VIRTUAL] Roxadustat Lowers Low-Density Lipoprotein Cholesterol in Patients with Anemia of CKD (On-Demand) - Oct 11, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_1586;
Treatment with roxadustat vs. placebo or epoetin alfa lowered LDL-C in patients with NDD-CKD and DD-CKD, respectively. Funding: Commercial Support
- Epogen, Procrit (epoetin alfa) / Amgen, Evrenzo (roxadustat) / Astellas, AstraZeneca, FibroGen
[VIRTUAL] Efficacy and Safety of Roxadustat in Patients with Dialysis-Dependent CKD, Anemia, and Heart Failure (On-Demand) - Oct 11, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_1568;
Roxadustat was efficacious vs. epoetin alfa for increasing Hb levels and reducing mean monthly IV iron use in DD-CKD patients with HF. The safety and tolerability profile was similar to the overall population and consistent with that observed in this patient subgroup.
- Epogen, Procrit (epoetin alfa) / Amgen, Aranesp (darbepoetin alfa) / Amgen, Kyowa Hakko Kirin, Triferic (soluble ferric pyrophosphate) / Rockwell Medical
[VIRTUAL] Triferic (Ferric Pyrophosphate Citrate, FPC) Maintains Hemoglobin and Reduces IV Iron: Results from a Single-Site 2-Year Observational Analysis (On-Demand) - Oct 11, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_912;
The findings of this real-world observational study align with those of clinical trials in terms of reduction of IV Fe use and maintenance of Hgb. ESA was gradually reduced and the KDQoL showed a trend to improvement in the burden and symptoms of kidney disease.
- Epogen, Procrit (epoetin alfa) / Amgen, Evrenzo (roxadustat) / Astellas, AstraZeneca, FibroGen
[VIRTUAL] Subgroup Analyses of Efficacy of Roxadustat for Treatment of Anemia in Patients with Incident Dialysis-Dependent CKD (On-Demand) - Oct 11, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_907;
The efficacy of roxadustat vs. epoetin alfa for improving Hb level and reducing IV iron use was consistent across prespecified subgroups in the ID-DD population. Roxadustat reduced MACE and MACE+ vs.
- Epogen, Procrit (epoetin alfa) / Amgen, Evrenzo (roxadustat) / Astellas, AstraZeneca, FibroGen
[VIRTUAL] Roxadustat Lowers Risk of Red Blood Cell Transfusion in Patients with Anemia of CKD (On-Demand) - Oct 11, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_905;
Roxadustat markedly and significantly reduced the risk of RBC transfusion during anemia treatment compared with placebo in NDD CKD and, versus epoetin alfa in DD CKD in the pooled patient populations. Funding: Commercial Support
- Epogen, Procrit (epoetin alfa) / Amgen, Evrenzo (roxadustat) / Astellas, AstraZeneca, FibroGen
[VIRTUAL] Risk of Transfusion in Patients with Dialysis-Dependent CKD Increases with Hemoglobin Levels <10 g/dL vs. ≥10 g/dL: Pooled Results from Roxadustat Phase 3 Studies (On-Demand) - Oct 11, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_900;
In US-based patients with DD-CKD and anemia treated with roxadustat, the risk for transfusion was approximately 5 times higher in patients with Hb <10 g/dL vs. those with Hb ≥10 g/dL, regardless of treatment arm. Funding: Commercial Support
- || Epogen, Procrit (epoetin alfa) / Amgen
Clinical, Journal: EPO treatment does not alter acute serum profiles of GFAP and S100B after TBI: A brief report on the Australian EPO-TBI clinical trial. (Pubmed Central) - Oct 9, 2020
Elevated serum concentrations of GFAP and S100B after TBI reflect a robust, acute glial response to injury. Consistent with lack of improved outcome in TBI patients treated with EPO and prior findings on neuronal and axonal markers, glial biomarker concentrations and acute profiles were not affected by EPO.
- ||| Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Trial completion date: COMMANDS: A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Na (clinicaltrials.gov) - Sep 30, 2020
P3, N=350, Recruiting, Sponsor: Celgene
Consistent with lack of improved outcome in TBI patients treated with EPO and prior findings on neuronal and axonal markers, glial biomarker concentrations and acute profiles were not affected by EPO. Trial completion date: Sep 2023 --> Oct 2022
- || Epogen, Procrit (epoetin alfa) / Amgen
Clinical, Journal: Optimal EPO dosing in hemodialysis patients using a non-linear model predictive control approach. (Pubmed Central) - Sep 30, 2020
Based on a model of erythropoiesis we formulate a non-linear model predictive control (NMPC) algorithm for the individualized optimization of epoetin alfa (EPO) doses...An appropriate control is feasible in the tested patients under the assumption that the controlled quantity is measured regularly and that continuous EPO administration is adjusted on a daily, weekly or monthly basis. Further, the controller satisfactorily handles the following challenging problems in simulations: bleedings, missed administrations and dosing errors.
- Epogen, Procrit (epoetin alfa) / Amgen
[VIRTUAL] Blue Rubber Bleb Nevus Syndrome: Incidental Finding via Colonoscopy in an Asymptomatic Male () - Sep 15, 2020 - Abstract #ACG2020ACG_1166;
Several anti-angiogenic agents including corticosteroids, sirolimus, interferon-a, and octreotide have been found to control GI bleeding while reducing the need for transfusions. This is an incidental, asymptomatic case of BRBNS which can be added to the already known limited reported cases.
- ||| Epogen, Procrit (epoetin alfa) / Amgen, Retacrit (epoetin alfa biosimilar) / Stada, Norbitec, Pfizer
Arterial and venous thrombosis complicating coronary artery bypass grafting after use of epoetin alfa-epbx https://t.co/fScAy0Q54C (Twitter) - Aug 29, 2020
- ||| Vafseo (vadadustat) / Akebia Therap, Mitsubishi Tanabe
Trial completion, Enrollment change: Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa (clinicaltrials.gov) - Aug 8, 2020
P2, N=175, Completed, Sponsor: Akebia Therapeutics
This is an incidental, asymptomatic case of BRBNS which can be added to the already known limited reported cases. Active, not recruiting --> Completed | N=125 --> 175
- || Vafseo (vadadustat) / Akebia Therap, Mitsubishi Tanabe
Trial completion: Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease (clinicaltrials.gov) - Aug 7, 2020
P1b, N=46, Completed, Sponsor: Akebia Therapeutics
Active, not recruiting --> Completed | N=125 --> 175 Active, not recruiting --> Completed
- || Epogen, Procrit (epoetin alfa) / Amgen, Retacrit (epoetin alfa biosimilar) / Stada, Norbitec, Pfizer
Clinical, Journal: Long-term Safety of Epoetin Alfa-epbx for the Treatment of Anemia in ESKD: Pooled Analyses of Randomized and Open-label Studies. (Pubmed Central) - Aug 1, 2020
P3
This study was funded by Hospira Inc, which was acquired by Pfizer Inc in September 2015. ClinicalTrials.gov EPOE-10-13 (NCT01473420); EPOE-10-01 (NCT01473407); EPOE-11-04 (NCT01628120); EPOE-11-03 (NCT01628107).
- ||| Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Trial completion date: COMMANDS: A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Na (clinicaltrials.gov) - Jul 16, 2020
P3, N=350, Recruiting, Sponsor: Celgene
ClinicalTrials.gov EPOE-10-13 (NCT01473420); EPOE-10-01 (NCT01473407); EPOE-11-04 (NCT01628120); EPOE-11-03 (NCT01628107). Trial completion date: Dec 2026 --> Sep 2023
- | Epogen (epoetin alfa) / Amgen, NN1213 / Novo Nordisk
Enrollment closed, Enrollment change, Trial completion date: Erythropoietin to Prevent Unnecessary Transfusions In Patients With Cyanotic CHD - A Prospective Control Trial (clinicaltrials.gov) - Jul 13, 2020
P2, N=5, Active, not recruiting, Sponsor: University of California, San Diego
Trial completion date: Dec 2026 --> Sep 2023 Recruiting --> Active, not recruiting | N=40 --> 5 | Trial completion date: Feb 2022 --> Mar 2021
- | Epogen (epoetin alfa) / Amgen, NN1213 / Novo Nordisk
Trial completion: Neonatal Erythropoietin And Therapeutic Hypothermia Outcomes in Newborn Brain Injury (NEATO) (clinicaltrials.gov) - Jul 13, 2020
P1/2, N=50, Completed, Sponsor: University of California, San Francisco
Recruiting --> Active, not recruiting | N=40 --> 5 | Trial completion date: Feb 2022 --> Mar 2021 Active, not recruiting --> Completed
- || Epogen, Procrit (epoetin alfa) / Amgen
Clinical, Retrospective data, Journal: Definition and Validation of a Novel Metric of Erythropoiesis-Stimulating Agent Response in Hemodialysis Patients. (Pubmed Central) - Jul 4, 2020
The poor response group received a higher median epoetin alfa dose (160 U/kg/week) compared to the excellent response group (68.8 U/kg/week; P < .001) with a similar number of dose changes between the groups. AUC-HGB is a valid marker of epoetin alfa response and should be considered in future analyses of larger populations.
- ||||||| Jesduvroq (daprodustat) / GSK, Kyowa Kirin
Trial completion: Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD) (clinicaltrials.gov) - Jun 25, 2020
P3, N=407, Completed, Sponsor: GlaxoSmithKline
AUC-HGB is a valid marker of epoetin alfa response and should be considered in future analyses of larger populations. Active, not recruiting --> Completed
- || Epogen, Procrit (epoetin alfa) / Amgen
Clinical, Journal, HEOR: Economic Benefits of Switching From Intravenous to Subcutaneous Epoetin Alfa for the Management of Anemia in Hemodialysis Patients. (Pubmed Central) - Jun 19, 2020
Given the cost sparing advantages without compromising care while achieving comparable hemoglobin levels, HD units should consider converting to SQ mode of administration. The study was not registered on a publicly accessible registry as it was a retrospective chart review and exempted from review by the Research Ethics Board of the former Regina Qu'Appelle Health Region.
- || Vafseo (vadadustat) / Akebia Therap, Mitsubishi Tanabe
Enrollment change: Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease (clinicaltrials.gov) - Jun 16, 2020
P1b, N=46, Active, not recruiting, Sponsor: Akebia Therapeutics
The study was not registered on a publicly accessible registry as it was a retrospective chart review and exempted from review by the Research Ethics Board of the former Regina Qu'Appelle Health Region. N=35 --> 46
- ||| Epogen, Procrit (epoetin alfa) / Amgen
Clinical data, Clinical guideline, Review, Journal: Epoetin alfa for the treatment of myelodysplastic syndrome-related anemia: A review of clinical data, clinical guidelines, and treatment protocols. (Pubmed Central) - May 23, 2020
The effectiveness of biosimilar epoetin alfa (Binocrit, Sandoz) to correct anemia in lower-risk MDS patients has also been demonstrated in a retrospective, single-center, observational study. The recent approval of epoetin alfa by the EMA in this setting will provide clinicians with a welcome, approved treatment option for lower-risk MDS.
- ||| Epogen (epoetin alfa) / Amgen
Clinical, Clinical guideline, Review, Journal: Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. (Pubmed Central) - May 17, 2020
Iron replacement may be used to improve hemoglobin response and reduce RBC transfusions for patients receiving ESA with or without iron deficiency. Additional information is available at www.asco.org/supportive-care-guidelines and www.hematology.org/guidelines.
- |||| Epogen, Procrit (epoetin alfa) / Amgen
Clinical: Given risk of hypercaogulability in COVID-19, is there a concern about use of Epogen ,any recommendation in ESKD patients with COVID? #askrenal @hswapnil @NephRodby @kidney_boy @edgarvlermamd Just curious (Twitter) - May 12, 2020
- ||||| Epogen, Procrit (epoetin alfa) / Amgen, Retacrit (epoetin alfa biosimilar) / Stada, Norbitec, Pfizer
Clinical: #OpenAccess Long-term Safety of Epoetin Alfa-epbx for the Treatment of Anemia in ESKD: Pooled Analyses of Randomized and Open-label Studies https://t.co/wop0eFpwWn @sfishbane @IUKidney @HofstraKidney #anemia #ESKD #VisualAbstract (Twitter) - Apr 18, 2020
- ||| Epogen (epoetin alfa) / Amgen
Clinical, Clinical guideline, Journal: Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update. (Pubmed Central) - Apr 10, 2020
Iron replacement may be used to improve hemoglobin response and reduce RBC transfusions for patients receiving ESA with or without iron deficiency. Additional information is available at www.asco.org/supportive-care-guidelines and www.hematology.org/guidelines .
- ||| Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Trial completion date: COMMANDS: A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Na (clinicaltrials.gov) - Apr 8, 2020
P3, N=350, Recruiting, Sponsor: Celgene
Additional information is available at www.asco.org/supportive-care-guidelines and www.hematology.org/guidelines . Trial completion date: Nov 2022 --> Dec 2026
- || Jesduvroq (daprodustat) / GSK, Kyowa Kirin
Phase classification, Trial completion date, Trial primary completion date: Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP) (clinicaltrials.gov) - Apr 8, 2020
P2, N=62, Recruiting, Sponsor: GlaxoSmithKline
Trial completion date: Nov 2022 --> Dec 2026 Phase classification: P2a --> P2 | Trial completion date: May 2020 --> Jul 2020 | Trial primary completion date: May 2020 --> Jul 2020
- | Epogen (epoetin alfa) / Amgen
Trial primary completion date, Combination therapy: NCI-2009-01173: Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia (clinicaltrials.gov) - Apr 7, 2020
P3, N=249, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Phase classification: P2a --> P2 | Trial completion date: May 2020 --> Jul 2020 | Trial primary completion date: May 2020 --> Jul 2020 Trial primary completion date: Dec 2019 --> Jul 2019
- Epogen, Procrit (epoetin alfa) / Amgen, Aranesp (darbepoetin alfa) / Amgen, Kyowa Hakko Kirin
Conversion from Epoetin Alfa to Darbepoetin Alfa in Hemodialysis Patients: Effectiveness and Variability in Anemia Treatment () - Mar 27, 2020 - Abstract #NKFCSM2020NKF_CSM_190;
Research findings suggested long-acting treatment induces less hemoglobin variability (results based on the six months of follow- up). The hemodialysis patients will benefit from the new treatment in terms of hemoglobin stability with less doses administration with the possibility of reducing adverse health outcomes.
- Epogen, Procrit (epoetin alfa) / Amgen, Evrenzo (roxadustat) / Astellas, AstraZeneca, FibroGen
Roxadustat Lowers Risk of RBC Transfusion in Patients with Anemia of CKD () - Mar 27, 2020 - Abstract #NKFCSM2020NKF_CSM_185;
The hemodialysis patients will benefit from the new treatment in terms of hemoglobin stability with less doses administration with the possibility of reducing adverse health outcomes. Roxadustat markedly and significantly reduced the risk of RBC transfusion during anemia treatment compared with placebo in NDD CKD and, versus epoetin alfa in DD CKD in the pooled patient populations.
- Epogen, Procrit (epoetin alfa) / Amgen
A Novel Nurse Based Anemia Management in Dialysis Patients in Qatar: A Retrospective Cohort Study () - Mar 27, 2020 - Abstract #NKFCSM2020NKF_CSM_183;
Nurse based anemia management in hemodialysis patients achieved better outcomes than traditional anemia management regarding Hg within target range, number of patients in target Ferritin level and extreme Hg levels. The new model was cost effective.
- | Epogen (epoetin alfa) / Amgen
Enrollment status, Trial completion date, Trial primary completion date: CD71 in Dried Blood Spots in Healthy Males (clinicaltrials.gov) - Mar 17, 2020
P1, N=24, Enrolling by invitation, Sponsor: Sports Medicine Research and Testing Laboratory
The new model was cost effective. Recruiting --> Enrolling by invitation | Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Nov 2019 --> Nov 2020
- || Vafseo (vadadustat) / Akebia Therap, Mitsubishi Tanabe
Enrollment closed: Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease (clinicaltrials.gov) - Mar 9, 2020
P1b, N=35, Active, not recruiting, Sponsor: Akebia Therapeutics
Recruiting --> Enrolling by invitation | Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Nov 2019 --> Nov 2020 Recruiting --> Active, not recruiting
- | Epogen, Procrit (epoetin alfa) / Amgen
Journal: Potential life-years gained over a 5-year period by correcting DOPPS-identified modifiable practices in haemodialysis: results from the European MONITOR-CKD5 study. (Pubmed Central) - Mar 9, 2020
P=N/A
Recruiting --> Active, not recruiting Optimal management of the six modifiable haemodialysis practices may achieve 6.2% increase in 5-year survival.
- Epogen, Procrit (epoetin alfa) / Amgen
[VIRTUAL] IDENTIFYING PREDICTORS OF HIGH-COST MULTIPLE SCLEROSIS PATIENTS- A MACHINE LEARNING APPROACH () - Mar 8, 2020 - Abstract #ISPOR2020ISPOR_356;
In predicting high-cost patients, ML methods provided a significant improvement over the logistic regression model. Our findings can be used to guide further research to proactively manage care and reduce healthcare spending.
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, Epogen, Procrit (epoetin alfa) / Amgen, Neupogen (filgrastim) / Kyowa Hakko Kirin, Roche, Amgen
[VIRTUAL] TRENDS IN AVERAGE SALES PRICES OF BIOLOGICS REIMBURSED BY THE MEDICARE PART B PROGRAM (FIRST QUARTER 2010-FIRST QUARTER 2020) () - Mar 8, 2020 - Abstract #ISPOR2020ISPOR_65;
CONCLUSIONS The price of biologics paid by the Medicare Part B increased more than the consumer price index in the period of analysis. Prices of reference biologics with biosimilar competition increased at a lower rate than biologics without biosimilar competition.
- | Epogen (epoetin alfa) / Amgen, Musredo (molidustat) / Bayer, Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Journal: Effects of Molidustat in the Treatment of Anemia in Chronic Kidney Disease. (Pubmed Central) - Mar 4, 2020
Prices of reference biologics with biosimilar competition increased at a lower rate than biologics without biosimilar competition. The overall phase 2 efficacy and safety profile of molidustat in patients with CKD and anemia enables the progression of its development into phase 3.
- || Epogen, Procrit (epoetin alfa) / Amgen, Neupogen (filgrastim) / Kyowa Hakko Kirin, Roche, Amgen
Sorry auto corrected neupogen and epogen! (Twitter) - Mar 4, 2020
- | Epogen (epoetin alfa) / Amgen
Trial completion, Surgery: Erythropoetin Neuroprotection for Neonatal Cardiac Surgery (clinicaltrials.gov) - Feb 7, 2020
P1/2, N=62, Completed, Sponsor: Baylor College of Medicine
The overall phase 2 efficacy and safety profile of molidustat in patients with CKD and anemia enables the progression of its development into phase 3. Active, not recruiting --> Completed